Atlas Trials

Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Clinical trial NCT07054632 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07054632
Sponsor
Innostellar Biotherapeutics Co.,Ltd
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Inherited Retinal Dystrophy Associated With RPE65 Mutations
Start date
2023-09-13
Primary completion
2025-08-13
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.